Bicycle TherapeuticsFRA:50BA 56 PB Ratio is 0.50 as of Jun. 26, 2026, which is 79% below its 10-year median of 2.43. GuruFocus rates FRA:50BA with a GF Score™ of 56/100 and a GF Value™ of €13.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,233 Biotechnology companies, Bicycle Therapeutics ranks better than 94.65% on this metric.
Bicycle Therapeutics PLC stock PB Ratio (=0.5) is close to 10-year low of 0.49.
The historical rank and industry rank for Bicycle Therapeutics's PB Ratio or its related term are showing as below:
FRA:50BA'
s PB Ratio Range Over the Past 10 Years
Min: 0.49 Med: 2.43 Max: 9.03
Current: 0.5
During the past 9 years, Bicycle Therapeutics's highest PB Ratio was 9.03. The lowest was 0.49. And the median was 2.43.
FRA:50BA's PB Ratio is ranked better than 94.65% of 1233
companies
in the Biotechnology industry
Industry Median: 2.8
vs FRA:50BA: 0.50
During the past 12 months, Bicycle Therapeutics's average Book Value Per Share Growth Rate was -25.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -1.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 9.70% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Bicycle Therapeutics was 24.50% per year. The lowest was -1.00% per year. And the median was 9.95% per year.
Back to Basics: PB Ratio
Bicycle Therapeutics (FRA:50BA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Bicycle Therapeutics PB Ratio Related Terms
Bicycle Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Bicycle Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Bicycle Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bicycle Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bicycle Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Bicycle Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Bicycle Therapeutics (FRA:50BA) has a PB Ratio of 0.50 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bicycle Therapeutics and its competitors. This is 79% below median its historical median of 2.43. Over the past decade, Bicycle Therapeutics' PB Ratio has ranged from 0.49 to 9.03. According to the industry distribution chart, Bicycle Therapeutics ranks #66 out of 1233 companies in the Biotechnology industry, placing it in the top 5.4%.
Is Bicycle Therapeutics' PB Ratio too high?
Bicycle Therapeutics' current PB Ratio of 0.50 is 79% below median its 10-year median of 2.43. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 9.03. The Biotechnology industry median PB Ratio is 2.80. Bicycle Therapeutics' value of 0.50 is 82.1% below this industry median. Based on the distribution chart, Bicycle Therapeutics ranks #66 out of 1233 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Bicycle Therapeutics has a GF Score™ of 56/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bicycle Therapeutics' PB Ratio compare to ABEO and DMAC?
According to the Biotechnology industry distribution chart, Bicycle Therapeutics ranks #66 out of 1233 companies for PB Ratio. This places Bicycle Therapeutics in the top 5% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.80. Bicycle Therapeutics' value of 0.50 is 82.1% below this benchmark. Historically, Bicycle Therapeutics' own PB Ratio has ranged from 0.49 to 9.03 over the past decade. While the company's 10-year median is 2.43 vs. the industry median of 2.80, Bicycle Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,233 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bicycle Therapeutics's current PB Ratio of 0.50 is 82.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Bicycle Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bicycle Therapeutics's current PB Ratio is 0.50, which is 79% below median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicycle Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Bicycle Therapeutics (FRA:50BA) is currently considered Possible Value Trap. The stock's GF Value™ is €13.24, compared to a current price of €3.46 — trading 73.9% below its estimated fair value. The current PB Ratio is 0.50, which is 79% below median its 10-year median of 2.43 and 82.1% below the Biotechnology industry median of 2.80. Bicycle Therapeutics' overall GF Score™ is 56/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Bicycle Therapeutics (FRA:50BA), the current PB Ratio is 0.50 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bicycle Therapeutics (FRA:50BA) Overvalued in 2026?
Based on GuruFocus' analysis, Bicycle Therapeutics stock appears to be undervalued.
The current stock price of €3.46 is trading 73.9% below its estimated GF Value™ of €13.24.
GuruFocus considers Bicycle Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:50BA:
PB Ratio: 0.50 (79% below median its 10-year median of 2.43)
GF Value™: €13.24 vs. price of €3.46 (73.9% below fair value)
Industry Position: 82.1% below the Biotechnology median (#66 of 1233)
No single metric tells the full story. See the FRA:50BA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United Kingdom.
56GF Score
Get the complete analysis for FRA:50BA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:50BA has been successfully added to your 
